Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Cross Below 200-Day Moving Average – Should You Sell?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.86 and traded as low as $0.55. Marinus Pharmaceuticals shares last traded at $0.55, with a volume of 260 shares changing hands.

Analysts Set New Price Targets

Several brokerages have recently commented on MRNS. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Jefferies Financial Group restated a “hold” rating and issued a $0.50 price objective (down from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. StockNews.com began coverage on Marinus Pharmaceuticals in a research report on Saturday. They issued a “sell” rating on the stock. Royal Bank of Canada lowered their price objective on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research report on Friday, October 25th. Finally, HC Wainwright restated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Stock Performance

The firm has a fifty day moving average price of $0.48 and a 200 day moving average price of $0.86. The stock has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03.

Institutional Trading of Marinus Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at $36,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at $54,000. World Investment Advisors LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 3rd quarter valued at $104,000. Deltec Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals during the 4th quarter valued at $107,000. Finally, XTX Topco Ltd increased its position in shares of Marinus Pharmaceuticals by 1,564.7% in the 4th quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after acquiring an additional 206,614 shares during the period. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.